Legal & General Group PLC Cerevel Therapeutics Holdings, Inc. Transaction History

Legal & General Group PLC

$440 Billion
Q2 2024

A detailed history of Legal & General Group PLC transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 79,884 shares of CERE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

79,884

Previous 72,607 10.02%

Holding current value

Previous $3.07 Million 6.42%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.96 - $42.75 $283,511 - $311,091	7,277 Added 10.02%	79,884 $3.27 Million
Q1 2024 May 14, 2024	BUY	$40.88 - $43.27 $86,093 - $91,126	2,106 Added 2.99%	72,607 $3.07 Million
Q4 2023 Feb 15, 2024	BUY	$20.27 - $42.44 $211,618 - $443,073	10,440 Added 17.38%	70,501 $2.99 Million
Q3 2023 Nov 14, 2023	BUY	$20.26 - $31.91 $51,419 - $80,987	2,538 Added 4.41%	60,061 $1.31 Million
Q2 2023 Aug 14, 2023	BUY	$23.9 - $35.38 $104,682 - $154,964	4,380 Added 8.24%	57,523 $1.83 Million
Q1 2023 May 15, 2023	BUY	$22.82 - $35.32 $57,894 - $89,606	2,537 Added 5.01%	53,143 $1.3 Million
Q4 2022 Feb 14, 2023	SELL	$25.35 - $31.96 $13,714 - $17,290	-541 Reduced 1.06%	50,606 $1.6 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $115,540 - $187,674	4,531 Added 9.72%	51,147 $1.45 Million
Q2 2022 Aug 22, 2022	BUY	$20.62 - $37.15 $245,006 - $441,416	11,882 Added 34.21%	46,616 $1.23 Million
Q1 2022 May 16, 2022	BUY	$23.5 - $35.38 $426,431 - $642,005	18,146 Added 109.39%	34,734 $1.22 Million
Q4 2021 Feb 14, 2022	BUY	$29.21 - $44.64 $13,728 - $20,980	470 Added 2.92%	16,588 $538,000
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $208,794 - $381,545	9,821 Added 155.96%	16,118 $475,000
Q2 2021 Aug 12, 2021	BUY	$12.56 - $29.69 $79,090 - $186,957	6,297 New	6,297 $161,000

Others Institutions Holding CERE

# of Institutions

270

Shares Held

155M

Call Options Held

2.19M

Put Options Held

3.92M

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Cerevel Therapeutics Holdings, Inc. Transaction History